

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1992	514/381	US-PGPUB; USPAT	OR	OFF	2007/06/15 11:01
L2	1331	514/570	US-PGPUB; USPAT	OR	OFF	2007/06/15 11:01
L3	380	548/250	US-PGPUB; USPAT	OR	OFF	2007/06/15 11:01
L4	191	562/468	US-PGPUB; USPAT	OR	OFF	2007/06/15 11:01

SEARCH REQUEST FORM**Scientific and Technical Information Center**

Requester's Full Name: Robert (Cherly) Shaw Examiner #: 79521 Date: 5/14/07
 Art Unit: 1626 Phone Number: 202-0707 Serial Number: 10/524,704
 Mail Box and Bldg/Room Location: Room 5710 Results Format Preferred (circle): PAPER DISK E-MAIL


If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Asb phenone ptn
 Inventors (please provide full names): Cube et al

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



* R_1 & R_4 are sub

* W is tetrahydra,
 CO_2H , NH_2SO_2 alkyl
 or $CONHCO$ -alkyl

* X is O, S, N or
 a bond

* Y is O or S
 * m, n is 0 ~ 6

I sub methods of use
 of cpd I (see claim 16 ~ 22)

STAFF USE ONLY**Type of Search****Vendors and cost where applicable**

Searcher: _____

NA Sequence (#) _____

STN _____


Searcher Phone #: _____

AA Sequence (#) _____

Dialog _____

=> => d que stat l24

L6 SCR 464
 L7 SCR 1518
 L8 SCR 1470
 L9 SCR 1839
 L10 SCR 2043
 L12 SCR 1146
 L19 SCR 1803
 L21 STR



VAR G1=14/16/19/23

REP G2=(0-6) CH2

REP G3=(0-15) A

VAR G4=O/S

VAR G6=34/35/36

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 15

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 3

GGCAT IS UNS AT 14

GGCAT IS SAT AT 35

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M6 C AT 3

ECOUNT IS E1 C E4 N E0 O E0 P E0 S E0 Si AT 14

ECOUNT IS M1-X6 C AT 17

ECOUNT IS M1-X6 C AT 20

ECOUNT IS X6 C AT 34

ECOUNT IS M3-X7 C AT 35

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE




L24 621 SEA FILE=REGISTRY SSS FUL (((((L6 OR L7 OR L8) OR L19) AND L9
 AND L12) NOT L10) AND L21)

100.0% PROCESSED 502494 ITERATIONS
SEARCH TIME: 00.00.10

621 ANSWERS

=> d que stat 139

L6 SCR 464
L7 SCR 1518
L8 SCR 1470
L9 SCR 1839
L10 SCR 2043
L12 SCR 1146
L19 SCR 1803
L21 STR



VAR G1=14/16/19/23
REP G2=(0-6) CH2
REP G3=(0-15) A
VAR G4=O/S
VAR G6=34/35/36
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 15
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 3
GGCAT IS UNS AT 14
GGCAT IS SAT AT 35
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M6 C AT 3
ECOUNT IS E1 C E4 N E0 O E0 P E0 S E0 Si AT 14
ECOUNT IS M1-X6 C AT 17
ECOUNT IS M1-X6 C AT 20
ECOUNT IS X6 C AT 34
ECOUNT IS M3-X7 C AT 35

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED


10/524,704

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L24 621 SEA FILE=REGISTRY SSS FUL (((((L6 OR L7 OR L8) OR L19) AND L9
AND L12) NOT L10) AND L21)

L37 STR



VAR G1=14/16/19/23

REP G2=(0-6) CH2

REP G3=(0-15) A

VAR G4=O/S

VAR G6=34/35/36

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 15

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 3

GGCAT IS UNS AT 14

GGCAT IS SAT AT 35

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E6 C AT 3

ECOUNT IS E1 C E4 N E0 O E0 P E0 S E0 Si AT 14

ECOUNT IS M1-X6 C AT 17

ECOUNT IS M1-X6 C AT 20

ECOUNT IS X6 C AT 34

ECOUNT IS M3-X7 C AT 35

GRAPH ATTRIBUTES:

RSPEC 6

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L39 575 SEA FILE=REGISTRY SUB=L24 SSS FUL L37


100.0% PROCESSED 621 ITERATIONS

SEARCH TIME: 00.00.01

575 ANSWERS

=> d que stat 145

L6 SCR 464
 L7 SCR 1518
 L8 SCR 1470
 L9 SCR 1839
 L10 SCR 2043
 L12 SCR 1146
 L19 SCR 1803
 L21 STR



VAR G1=14/16/19/23

REP G2=(0-6) CH2

REP G3=(0-15) A

VAR G4=O/S

VAR G6=34/35/36

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 15

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 3

GGCAT IS UNS AT 14

GGCAT IS SAT AT 35

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M6 C AT 3

ECOUNT IS E1 C E4 N E0 O E0 P E0 S E0 Si AT 14

ECOUNT IS M1-X6 C AT 17

ECOUNT IS M1-X6 C AT 20

ECOUNT IS X6 C AT 34

ECOUNT IS M3-X7 C AT 35

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L24 621 SEA FILE=REGISTRY SSS FUL (((((L6 OR L7 OR L8) OR L19) AND L9
 AND L12) NOT L10) AND L21)

L43

STR



Page 1-A

@35

Page 1-B

VAR G1=14/16/19/23

REP G2=(0-6) CH2

REP G3=(0-15) A

VAR G4=O/S

VAR G6=34/35/36

VAR G7=OH/X/43/45

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 15

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 3

GGCAT IS UNS AT 14

GGCAT IS SAT AT 35

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E6 C AT 3

ECOUNT IS E1 C E4 N E0 O E0 P E0 S E0 Si AT 14

ECOUNT IS M1-X6 C AT 17

ECOUNT IS M1-X6 C AT 20

ECOUNT IS X6 C AT 34

ECOUNT IS M3-X7 C AT 35

ECOUNT IS X6 C AT 44

ECOUNT IS X6 C AT 45

GRAPH ATTRIBUTES:

RSPEC 6

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L45 332 SEA FILE=REGISTRY SUB=L24 SSS FUL L43

100.0% PROCESSED 621 ITERATIONS

332 ANSWERS

SEARCH TIME: 00.00.01



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[Sign In] [Regis
Entrez 2.0

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bool

Search PubMed for [] Go Clear

Limits Preview/Index History Clipboard Details

Display AbstractPlus Show 20 Sort by Send to

All: 1 Review: 1

1: Curr Opin Investig Drugs. 2001 Aug;2(8):1112-9.

Links

Glutamate receptor ligands as anxiolytics.

Chojnacka-Wójcik E, Kłodzinska A, Pilc A.

Institute of Pharmacology, Polish Academy of Sciences, Krakow,
Smetna. wojcik@if-pan.krakow.pl

The glutamatergic system has received considerable attention over recent years as a potential target for anxiolytic drugs. In spite of the pronounced anxiolytic-like effects of competitive and non-competitive antagonists of NMDA receptors in animal models of anxiety, these substances can not be regarded as potential anxiolytic drugs, mainly due to their side-effect profiles (eg, ataxia, myorelaxation, impairment of learning and memory processes and psychotomimetic effects). Antagonists and partial agonists of the glycine, receptor inhibit function of the NMDA receptor complex and evoke in animals an anxiolytic-like response. Although data concerning anti-anxiety-like effects of glycine, receptor antagonists are not very promising, studies are underway to develop new, brain-penetrating agents devoid of side effects. Further developments are necessary to more fully elucidate the possible involvement of AMPA/kainate receptors in anxiety. The recent discovery of metabotropic glutamate receptors, which modulate the function of the glutamatergic system, offers new hope for discovery of a new generation of anxiolytics. MPEP, a highly selective, brain penetrable, noncompetitive mGlu5 receptor antagonist, evokes anxiolytic-like effects in several animal models of anxiety, remaining remarkably free of side effects. LY-354740, a selective brain-penetrable group II mGlu receptor agonist, evokes marked anxiolytic-like effects in animal models of anxiety. LY-354740 causes mild sedation in mice, does not disturb motor coordination and has no potential to cause dependence. Therefore mGlu receptor ligands may become the anxiolytics of the future, free from the side effects characteristic of benzodiazepines.

PMID: 11892923 [PubMed - indexed for MEDLINE]

Related Links

- ▶ mGlu5 receptor antagonists: a novel class of anxiolytics. [Drug News Perspect. 2004]
- ▶ Riluzole, a glutamate release inhibitor, [Neuropharmacology Arch Pharmacol. 1998]
- ▶ Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. [Br J Pharmacol. 2001]
- ▶ Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. [Neuropharmacology. 2002]
- ▶ Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. [Neuropharmacology. 2007]

See all Related Articles...

Display AbstractPlus Show 20 Sort by Send to

[Write to the Help Desk](#)

L94 ANSWER 27 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2000:12845 USPATFULL Full-text
TITLE: Method of treating diabetes and related disease states
INVENTOR(S): Doeber, Thomas W., Scotch Plains, NJ, United States
Berger, Joel P., Hoboken, NJ, United States
Berger, Gregory D., Groton, CT, United States
Leibowitz, Mark D., San Diego, CA, United States
Moller, David E., Bedminster, NJ, United States
Olson, John T., Dayton, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Toupence, Richard B., Chicago, IL, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020382		20000201
	WO 9727847		19970807
APPLICATION INFO.:	US 1999-117654		19990104 (9)
	WO 1997-US1875		19970131
			19990104 PCT 371 date
			19990104 PCT 102(e) date
RELATED APPLN. INFO.:	Division of Ser. No. WO 1997-US1875, filed on 31 Jan 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-11025P	19960202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	McGinnis, James L., Rose, David L., Billups, Richard C.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1423	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

IT 194791-55-4P 194791-57-6P 194791-61-2P
194791-76-9P 194791-91-8P 194791-92-9P
194791-93-0P 194791-95-2P 194791-98-5P
194792-00-2P 194792-01-3P 194792-02-4P
194792-03-5P 194792-11-5P 194793-07-2P

(preparation of (phenoxypropylthio)phenylacetates and related compds. as antiobesity, antiatherosclerotic, and antidiabetic agents)


RN 194791-55-4 USPATFULL

CN Benzeneacetic acid, 3-chloro-4-[[3-[3-hydroxy-4-(1-oxopropyl)-2-propylphenoxy]propyl]thio]- (9CI) (CA INDEX NAME)




RN 194791-57-6 USPATFULL

CN Benzeneacetic acid, 3-chloro-4-[[3-[3-hydroxy-4-(1-oxobutyl)-2-propylphenoxy]propyl]thio]- (9CI) (CA INDEX NAME)




RN 194791-61-2 USPATFULL

CN Benzeneacetic acid, 3-chloro-4-[[3-[3-methoxy-4-(1-oxopropyl)-2-propylphenoxy]propyl]thio]- (9CI) (CA INDEX NAME)




RN 194791-76-9 USPATFULL

CN Benzeneacetic acid, 3-chloro-4-[[3-[2-(cyclopropylmethyl)-3-hydroxy-4-(1-oxopropyl)phenoxy]propyl]thio]- (9CI) (CA INDEX NAME)




RN 194791-91-8 USPATFULL

CN Benzeneacetic acid, 4-[[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]-3-chloro- (9CI) (CA INDEX NAME)




RN 194791-92-9 USPATFULL

CN Ethanone, 1-[4-[3-[[2-chloro-4-(1H-tetrazol-5-ylmethyl)phenyl]thio]propoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 194791-93-0 USPATFULL

CN Ethanone, 1-[4-[4-[[2-chloro-4-(1H-tetrazol-5-ylmethyl)phenyl]thio]butoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 194791-95-2 USPATFULL

CN 1-Propanone, 1-[4-[3-[[2-chloro-4-(1H-tetrazol-5-ylmethyl)phenyl]thio]propoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 194791-98-5 USPATFULL

CN 1-Propanone, 1-[4-[4-[[2-chloro-4-(1H-tetrazol-5-ylmethyl)phenyl]thio]butoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 194792-00-2 USPATFULL

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[3-[4-(1H-tetrazol-5-ylmethyl)phenoxy]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 194792-01-3 USPATFULL

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[4-[4-(1H-tetrazol-5-ylmethyl)phenoxy]butoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 194792-02-4 USPATFULL

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[3-[[4-(1H-tetrazol-5-ylmethyl)phenyl]thio]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 194792-03-5 USPATFULL

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]thio]butoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 194792-11-5 USPATFULL

CN Benzeneacetic acid, 4-[[3-(4-benzoyl-3-hydroxy-2-propylphenoxy)propyl]thio]-3-chloro- (9CI) (CA INDEX NAME)



RN 194793-07-2 USPATFULL

CN Benzeneacetic acid, 3-chloro-4-[3-[3-hydroxy-4-(1-oxopentyl)-2-propylphenoxy]propoxy]- (9CI) (CA INDEX NAME)



L94 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 1998:788753 HCAPLUS Full-text
 DOCUMENT NUMBER: 130:47486
 TITLE: Method of treating diabetes and related disease states
 INVENTOR(S): Doeber, Thomas W.; Berger, Joel P.; Berger, Gregory D.; Leibowitz, Mark D.; Moller, David E.; Olson, John T.; Patchett, Arthur A.; Toupence, Richard B.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 20 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847008	A	19981208	US 1997-797649	19970131
PRIORITY APPLN. INFO.:			US 1997-797649	19970131
OTHER SOURCE(S):	MARPAT 130:47486			

ED Entered STN: 16 Dec 1998


AB The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compds. Compns. and methods for the use of the compds. in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high d. lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed. The compds. of this invention may be used in combination with a sulfonylurea, fibrate, HMG-CoA reductase inhibitor, β -sitosterol inhibitor, cholesterol acyltransferase inhibitor, biguanides, cholestyramine, angiotensin II antagonist, melinamide, nicotinic acid, fibrinogen receptor antagonists, aspirin, α -glucosidase inhibitors, insulin secretagogue or insulin. The preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3- dichlorobenzeneacetic acid is presented.

IT 91361-47-6P 91361-49-8P 91361-51-2P
91361-53-4P 91361-55-6P 91361-57-8P
91361-64-7P 91361-67-0P 91362-27-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (acetylphenols for treating diabetes and related diseases)


RN 91361-47-6 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 91361-49-8 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 91361-51-2 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfinyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 91361-53-4 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 91361-55-6 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfinyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 91361-57-8 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfonyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 91361-64-7 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-2-fluoro- (9CI) (CA INDEX NAME)



RN 91361-67-0 HCAPLUS


CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]-2-fluoro-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 91362-27-5 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfinyl]-2-fluoro- (9CI) (CA INDEX NAME)



IT 91361-69-2 91361-70-5 91361-75-0
91361-77-2 91361-81-8 91361-83-0
91361-85-2 91361-87-4 91361-89-6
91361-91-0 91361-94-3 91361-96-5
91361-99-8 91362-01-5 91362-05-9

91362-09-3 91362-13-9 91362-15-1


91362-18-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study; unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acetylphenols for treating diabetes and related diseases)


RN 91361-69-2 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 91361-70-5 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-propenyl]sulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 91361-75-0 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-3-fluoro- (9CI) (CA INDEX NAME)




RN 91361-77-2 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]-3-fluoro- (9CI) (CA INDEX NAME)




RN 91361-81-8 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-3-chloro- (9CI) (CA INDEX NAME)




RN 91361-83-0 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfinyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 91361-85-2 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 91361-87-4 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]-3-chloro- (9CI) (CA INDEX NAME)




RN 91361-89-6 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfinyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 91361-91-0 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfonyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 91361-94-3 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]- (9CI) (CA INDEX NAME)




RN 91361-96-5 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 91361-99-8 HCAPLUS

CN Benzeneacetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-methylpropyl]thio]- (9CI) (CA INDEX NAME)




RN 91362-01-5 HCAPLUS

CN Benzenecetic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]- (9CI) (CA INDEX NAME)




RN 91362-05-9 HCAPLUS

CN Benzoic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]-3-fluoro- (9CI) (CA INDEX NAME)




RN 91362-09-3 HCAPLUS

CN Benzoic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]sulfonyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 91362-13-9 HCAPLUS

CN Benzoic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfinyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 91362-15-1 HCAPLUS

CN Benzoic acid, 4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 91362-18-4 HCAPLUS

CN Benzeneacetic acid, 4'-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]cyanoamino]- (9CI) (CA INDEX NAME)



L93 ANSWER 17 OF 115 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 18
 ACCESSION NUMBER: 1987:496724 HCAPLUS Full-text
 DOCUMENT NUMBER: 107:96724
 TITLE: Tetrazolylalkoxyphenols as allergy inhibitors and cardiovascular agents.
 INVENTOR(S): Carson, Matthew; LeMahieu, Ronald A.
 PATENT ASSIGNEE(S): Hoffmann-La Roche, Inc., USA
 SOURCE: U.S., 17 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4663332	A	19870505	US 1985-786386	19851010 <--
PRIORITY APPLN. INFO.:			US 1985-786386	19851010 <--
OTHER SOURCE(S):	CASREACT 107:96724; MARPAT 107:96724			

ED Entered STN: 19 Sep 1987


AB The title compds. [I; R1 = H, halo; R2 = H, alkanoyl; R3 = H, alkyl; A = O(CH2)nB, OCH2C6H4B; B = Q1, Q2; Het = 3- or 4-pyridyl; n = 3-8; m = 1-6] were prepared as allergy inhibitors and as cardiovascular agents. 1-[2-Hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl]ethanone, 3-(3-bromopropyl)pyridine·HCl, Et3N, Me2CO, and DMF were stirred for 5 h to give phenoxybutyltetrazolylpropylpyridine II and its 2-(pyridinylpropyl)tetrazolyl isomer. 1 Mg II/kg i.v. inhibited by 99% PAF-induced guinea pig bronchoconstriction. Tablets were prepared containing II 100, lactose 30, starch 6, microcryst. cellulose 30, and Mg stearate 1 mg.

IT 109914-47-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkylation of, by (bromopropyl)pyridine derivative)

RN 109914-47-8 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[3-(1H-tetrazol-5-yl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1997:184435 HCAPLUS Full-text

DOCUMENT NUMBER: 126:185890

TITLE: Derivatives of 4-alkoxy-3-propyl-2-hydroxyacetophenone with antiinflammatory and antiasthmatic activity.

INVENTOR(S): Kuchar, Miroslav; Culikova, Katerina; Brunova, Bohumila; Anderova, Eva; Svorcova, Marie; Lapka, Roman

PATENT ASSIGNEE(S): Galena, Czech Rep.

SOURCE: Czech Rep., 17 pp.

CODEN: CZXXED

DOCUMENT TYPE: Patent

LANGUAGE: Czech

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CZ 281130	B6	19960612	CZ 1993-1214	19930618 <--
PRIORITY APPLN. INFO.:			CZ 1993-1214	19930618 <--

OTHER SOURCE(S): CASREACT 126:185890; MARPAT 126:185890

ED Entered STN: 20 Mar 1997

AB Title compds. I are disclosed [wherein Y = O, S; Q = CH₂CO₂R or CO₂R; R = H, C1-3 alkyl, cation of an alkali metal or an organic base; when P = H or halo, Z = (CH₂)₂₋₄; when P = H, Z may also = CH₂CH(OH)CH₂]. Twenty synthetic examples of I and their intermediates are given, plus the results of several bioassays of selected I. For instance, thioetherification of 4-(3-chloropropoxy)-3-propyl-2-hydroxyacetophenone with 3-mercaptopbenzoic acid in 2-butanone in the presence of K₂CO₃ and KI gave 73% title compound II. The IC₅₀ of II for inhibition of 5-lipoxygenase was 1.20 µM in vitro. Several I inhibited LTD₄-induced bronchospasm in guinea pigs with an activity comparable to the known standard LY 171,883.


IT 94973-60-1P, [4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-chlorophenyl]acetic acid 187341-76-0P, 3-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]benzoic acid 187341-77-1P, 2-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]benzoic acid 187341-79-3P, 2-[[2-(4-Acetyl-3-hydroxy-2-propylphenoxy)ethyl]thio]benzoic acid 187341-80-6P, 2-[[4-(4-Acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]benzoic acid 187341-81-7P, 3-[[4-(4-Acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]benzoic acid 187341-85-1P, [4-[4-(4-Acetyl-3-hydroxy-2-propylphenoxy)butoxy]phenyl]acetic acid 187341-86-2P, [4-[4-(4-Acetyl-3-hydroxy-2-propylphenoxy)butoxy]-3-chlorophenyl]acetic acid 187341-87-3P, [4-[2-(4-Acetyl-3-hydroxy-2-propylphenoxy)ethoxy]-3-chlorophenyl]acetic acid 187341-88-4P, [4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenyl]acetic acid 187341-89-5P, 2-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]benzoic acid 187341-90-8P, 3-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]benzoic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkoxypropylhydroxyacetophenone derivs. as antiinflammatories and antiasthmatics)


RN 94973-60-1 HCAPLUS

CN Benzeneacetic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-chloro- (9CI) (CA INDEX NAME)




RN 187341-76-0 HCAPLUS

CN Benzoic acid, 3-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-
(9CI) (CA INDEX NAME)




RN 187341-77-1 HCAPLUS

CN Benzoic acid, 2-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-
(9CI) (CA INDEX NAME)




RN 187341-79-3 HCAPLUS

CN Benzoic acid, 2-[[2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl]thio]- (9CI)
(CA INDEX NAME)




RN 187341-80-6 HCAPLUS

CN Benzoic acid, 2-[[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]- (9CI)
(CA INDEX NAME)




RN 187341-81-7 HCAPLUS

CN Benzoic acid, 3-[[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]- (9CI)
(CA INDEX NAME)




RN 187341-85-1 HCAPLUS

CN Benzeneacetic acid, 4-[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butoxy]-
(9CI) (CA INDEX NAME)




RN 187341-86-2 HCAPLUS

CN Benzeneacetic acid, 4-[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butoxy]-3-
chloro- (9CI) (CA INDEX NAME)




RN 187341-87-3 HCAPLUS

CN Benzeneacetic acid, 4-[2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethoxy]-3-
chloro- (9CI) (CA INDEX NAME)




RN 187341-88-4 HCAPLUS

CN Benzeneacetic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-
(9CI) (CA INDEX NAME)




RN 187341-89-5 HCAPLUS

CN Benzoic acid, 2-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]- (9CI) (CA INDEX NAME)



RN 187341-90-8 HCAPLUS

CN Benzoic acid, 3-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]- (9CI) (CA INDEX NAME)




IT 187341-92-0, 3-[[2-(4-Acetyl-3-hydroxy-2-propylphenoxy)ethyl]thio]benzoic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of alkoxypropylhydroxyacetophenone derivs. as antiinflammatories and antiasthmatics)

RN 187341-92-0 HCAPLUS

CN Benzoic acid, 3-[[2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethyl]thio]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1997:739153 HCAPLUS Full-text
 DOCUMENT NUMBER: 128:70373
 TITLE: Monoclonal antibodies as surrogate receptors in a high throughput screen for compounds that enhance insulin sensitivity
 AUTHOR(S): Bright, Stuart W.; Gold, Gerald; Sage, Scott W.; Sportsman, J. Richard; Tinsley, Frank C.; Dominianni, Samuel J.; Schmiegel, Klaus K.; Kellam, Marcia L.; Fitch, Lora L.; Yen, Terence T.
 CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Life Sciences (1997), 61(23), 2305-2315
 CODEN: LIFSAK; ISSN: 0024-3205
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

ED Entered STN: 24 Nov 1997

AB Monoclonal antibodies (MoAbs) were made to a known insulin sensitivity enhancer (ISE) compound, CS-045. The MoAbs were characterized with respect to binding other known thiazolidinedione ISE compds. using a CS-045 labeled with b-phycoerythrin in a competitive particle concentration fluorescence immunoassay (PCFIA). By comparing the rank order of IC50 values for each compound to its resp. potency as an ISE, one MoAb (13E3) was selected for further characterization. This MoAb was also used as a surrogate receptor in a high throughput screen to identify novel compds. that compete for binding to CS-045. Some of the hits were found to have efficacy in reducing blood glucose. Subsequently, another group reported that several compds. with the core thiazolidinedione structure of the ISE compds. bound with high affinity to peroxisome proliferator-activating receptors (PPAR). Therefore, the authors used the MoAb assay to test these and other compds. that are known to bind to PPARy and noted crossreactivity with some of the compds.


IT 95928-70-4 95928-73-7 95928-74-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal antibodies as surrogate receptors in high throughput screen for insulin sensitivity enhancers in relation to hypoglycemic activity and binding to peroxisome proliferator-activating receptors)


RN 95928-70-4 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-(1H-tetrazol-5-yl)methyl]phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 95928-73-7 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-[2-(1H-tetrazol-5-yl)ethyl]phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 95928-74-8 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-[3-(1H-tetrazol-5-yl)propyl]phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1986:533529 HCAPLUS Full-text
 DOCUMENT NUMBER: 105:133529
 TITLE: Benzoic acid analogs
 INVENTOR(S): Nohara, Akira; Maki, Yoshitaka
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Eur. Pat. Appl., 25 pp:
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 180416	A2	19860507	EP 1985-307685	19851024 <--
EP 180416	A3	19861120		
R: AT, BE, CG, DE, FR, GB, IT, LI, LU, NL, SE				
JP 61129153	A	19860617	JP 1985-213579	19850925 <--
PRIORITY APPLN. INFO.:			JP 1984-U521	U 19841030 <--
			JP 1985-213579	A 19850925 <--
			WO 1984-JP521	A 19841030 <--

OTHER SOURCE(S): CASREACT 105:133529; MARPAT 105:133529

ED Entered STN: 18 Oct 1986


AB The title compds. (I; R1, R2 = H, alkyl; NR1R2 = 5- or 6-membered heterocycle; X = halo; n' = 2-4), useful as inflammation inhibitors and antiasthmatics, are prepared by esterification of II with Z(CH2)nNR1R2 (Z = OH, sulfonyloxy, halo) at 15-80° in the presence of a proton acceptor. Thus, 2 g II (X = 3-Br; 1-CO2H) and SOCl2 were refluxed in CHCl3 to form the acid chloride, which was treated with 0.4 g HO(CH2)2NMe2 in the presence of Et3N to give 2.1 g I.HCl (X = 3-Br; n = 2; R1 = R2 = Me; 1-CO2H), which had ID50 of 49 µmol/kg (orally) against LTD4-induced bronchial contraction in Hartley strain guinea pigs when administered 1 h prior to LTD4 dosing.

IT 87820-78-8 87820-79-9 103888-33-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (esterification of, with alkanolamines and their derivs., benzoate esters from)


RN 87820-78-8 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-chloro-
 (9CI) (CA INDEX NAME)




RN 87820-79-9 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-bromo-
 (9CI) (CA INDEX NAME)



RN 103888-33-1 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-fluoro-
(9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1989:172814 HCAPLUS Full-text

DOCUMENT NUMBER: 110:172814

TITLE: Hydroxyacetophenone-derived antagonists of the
peptidoleukotrienesAUTHOR(S): Brown, Frederick J.; Bernstein, Peter R.; Cronk, Laura
A.; Dosset, David L.; Hebbel, Kevin C.; Maduskuie,
Thomas P., Jr.; Shapiro, Howard S.; Vacek, Edward P.;
Yee, Ying K.; et al.CORPORATE SOURCE: Dep. Med. Chem., ICI Pharm. Group, Wilmington, DE,
19897, USASOURCE: Journal of Medicinal Chemistry (1989),
32(4), 807-26

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:172814

ED Entered STN: 12 May 1989


AB Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group. Although considerable attention has focused on FPL 55712-derived analogs, only limited investigations into alternatives for the standard 4-acetyl-3-hydroxy-2-propylphenoxy moiety have been reported. Therefore, an extensive study of modifications to the hydroxyacetophenone portion of toluic acid I (R = Ac, R1 = CO2H) was undertaken. Although no viable alternative to the 3-hydroxy moiety was discovered, replacements for the 2-Pr group, e.g., I (R = Ac, R1 = PhCH2, CH2CMe:CH2) and the 4-acetyl functionality, e.g., I (R = CO2Me, CO2Et, R1 = Pr) yielded potent antagonists. A number of compds. exhibited longer duration of action in vivo than FPL 55712.

IT 87807-96-3P 87807-98-5P 87808-00-2P
 87808-02-4P 87808-04-6P 87808-06-8P
 87808-16-0P 87808-18-2P 87808-19-3P
 87808-22-8P 87808-30-8P 87808-34-2P
 107223-63-2P 118682-99-8P 118683-00-4P
 118683-01-5P 118683-02-6P 118683-03-7P
 118683-04-8P 118683-05-9P 118683-06-0P
 118683-07-1P 118683-08-2P 118683-09-3P
 118683-10-6P 118683-11-7P 118683-13-9P
 118683-18-4P 118683-19-5P 118683-21-9P
 118683-25-3P 118683-26-4P 118683-27-5P
 118683-55-9P 118683-56-0P 118683-66-2P
 118683-67-3P 118683-68-4P 118683-73-1P
 118683-75-3P 118683-77-5P 118683-84-4P
 118713-63-6P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation and peptidoleukotriene antagonist activity of)

RN 87807-96-3 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA
INDEX NAME)


RN 87807-98-5 HCAPLUS

CN Benzoic acid, 2-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 87808-00-2 HCAPLUS

CN Benzoic acid, 3-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 87808-02-4 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 87808-04-6 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 87808-06-8 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 87808-16-0 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-ethoxy-
(9CI) (CA INDEX NAME)




RN 87808-18-2 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-2-bromo-
(9CI) (CA INDEX NAME)




RN 87808-19-3 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-2-methoxy-
(9CI) (CA INDEX NAME)




RN 87808-22-8 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI)
(CA INDEX NAME)




RN 87808-30-8 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-2-bromo-5-methoxy- (9CI) (CA INDEX NAME)




RN 87808-34-2 HCAPLUS

CN Benzeneacetic acid, 3-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 107223-63-2 HCAPLUS


CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-(1H-tetrazol-5-yl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 118682-99-8 HCAPLUS


CN Benzoic acid, 4-[(4-acetyl-3-hydroxyphenoxy)methyl]-3-methoxy- (9CI) (CA INDEX NAME)






RN 118683-18-4 HCAPLUS

CN Benzoic acid, 4-[[4-acetyl-3-(hexyloxy)phenoxy]methyl]-3-methoxy- (9CI)
(CA INDEX NAME)




RN 118683-19-5 HCAPLUS

CN Benzoic acid, 4-[[4-acetyl-3-(phenylmethoxy)phenoxy]methyl]-3-methoxy- (9CI)
(CA INDEX NAME)



RN 118683-21-9 HCAPLUS


CN Benzoic acid, 4-[[3-hydroxy-2-propyl-4-(trifluoroacetyl)phenoxy]methyl]-3-methoxy- (9CI)
(CA INDEX NAME)



RN 118683-25-3 HCAPLUS


CN Benzoic acid, 4-[[3-hydroxy-4-(1-oxopropyl)-2-propylphenoxy]methyl]-3-methoxy- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 118683-66-2 HCAPLUS

CN Ethanone, 1-[2-hydroxy-4-[[2-methoxy-4-(1H-tetrazol-5-yl)phenyl]methoxy]-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 118683-67-3 HCAPLUS

CN Ethanone, 1-[4-[[3-bromo-4-(1H-tetrazol-5-yl)phenyl]methoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 118683-68-4 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[2-(1H-tetrazol-5-yl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 118683-73-1 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(3-cyanopropoxy)- (9CI) (CA INDEX NAME)




RN 118683-75-3 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-[3-(1H-tetrazol-5-yl)propoxy]- (9CI) (CA INDEX NAME)



RN 118683-77-5 HCAPLUS


CN Methanesulfonamide, N-[3-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 118683-84-4 HCAPLUS

CN Benzoic acid, 4-[[4-acetyl-3-hydroxy-2-(3-phenyl-2-propenyl)phenoxy]methyl]-3-methoxy-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 118713-63-6 HCAPLUS

L93 ANSWER 15 OF 115 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 16
 ACCESSION NUMBER: 1987:617632 HCAPLUS Full-text
 DOCUMENT NUMBER: 107:217632
 TITLE: Preparation of tetrazolylphenoxypropoxyacetophenone derivatives as antiasthmatics and antiinflammatories
 INVENTOR(S): Nohara, Akira; Maki, Yoshitaka
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd. , Japan
 SOURCE: U.S., 10 pp. Division of U.S. 4,567,201.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4672073	A	19870609	US 1985-795103	19851105 <--
JP 59076038	A	19840428	JP 1982-186361	19821022 <--
US 4567201	A	19860128	US 1982-440297	19821109 <--
PRIORITY APPLN. INFO.:			JP 1982-186361	A 19821022 <--
			US 1982-440297	A3 19821109 <--
			JP 1982-189812	A 19821125 <--
			JP 1981-189812	A 19811125 <--

OTHER SOURCE(S): CASREACT 107:217632

ED Entered STN: 12 Dec 1987


AB The title compds. (I; R1 = H, OH; R2 = halo; R3 = tetrazolyl, carboxy) were prepared as antiasthmatic and antiinflammatories. Epoxypropyloxybenzonitrile derivative II (500 mg) was heated with 612 mg 4,2-ClCNC6H3OH in DMF containing Triton B at 170° for 1.5 h to give I (R1 = OH R2 = Cl, R3 = CN) which (760 mg) was heated with NaN3 and NH4Cl in DMF at 180° for 1 h to give 640 mg I (R1 = OH, R2 = Cl, R3 = 5-tetrazolyl) (III). III inhibited leukotriene induced contraction of guinea pig ileum with an IC50 of 4.1 + 10-9M.

IT 87820-73-3P 87820-74-4P 87820-75-5P
87820-77-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiasthmatic and antiinflammatory)


RN 87820-73-3 HCAPLUS

CN Ethanone, 1-[4-[3-[2-chloro-4-(1H-tetrazol-5-yl)phenoxy]-2-hydroxypropoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 87820-74-4 HCAPLUS

CN Ethanone, 1-[4-[3-[2-bromo-4-(1H-tetrazol-5-yl)phenoxy]-2-hydroxypropoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 87820-75-5 HCAPLUS

CN Ethanone, 1-[4-[3-[2-chloro-4-(1H-tetrazol-5-yl)phenoxy]propoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)



RN 87820-77-7 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-3-chloro- (9CI) (CA INDEX NAME)




IT 87820-74-4P 87820-75-5P 87820-77-7P
87820-78-8P 87820-79-9P 87820-81-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiinflammatory and antiasthmatic)


RN 87820-74-4 HCAPLUS

CN Ethanone, 1-[4-[3-[2-bromo-4-(1H-tetrazol-5-yl)phenoxy]-2-hydroxypropoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 87820-75-5 HCAPLUS

CN Ethanone, 1-[4-[3-[2-chloro-4-(1H-tetrazol-5-yl)phenoxy]propoxy]-2-hydroxy-3-propylphenyl]- (9CI) (CA INDEX NAME)




RN 87820-77-7 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-3-chloro- (9CI) (CA INDEX NAME)




RN 87820-78-8 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-chloro- (9CI) (CA INDEX NAME)



RN 87820-79-9 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3-bromo- (9CI) (CA INDEX NAME)



RN 87820-81-3 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-3-bromo- (9CI) (CA INDEX NAME)

L93 ANSWER 16 OF 115 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 17
 ACCESSION NUMBER: 1987:496440 HCAPLUS Full-text
 DOCUMENT NUMBER: 107:96440
 TITLE: Preparation of derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxy-carboxylic acids as allergy inhibitors and cardiovascular agent
 INVENTOR(S): Carson, Matthew; Han, Ru Jen L.; LeMahieu, Ronald A.
 PATENT ASSIGNEE(S): Hoffmann-La Roche, Inc., USA
 SOURCE: U.S., 26 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4672066	A	19870609	US 1985-725602	19850422 <--
PRIORITY APPLN. INFO.:			US 1985-725602	19850422 <--
OTHER SOURCE(S):	CASREACT 107:96440; MARPAT 107:96440			

ED Entered STN: 19 Sep 1987


AB Title compds. (I; R = H, alkyl; R1 = 3-pyridinyl, 4-pyridinyl, 3-pyridinyloxy, 3-pyridinylthio, 5-pyridinyl, imidazol-1-yl; R2 = H, alkoxy; A = CONH, CO2, NHCONH; Y = alkylene; Z = alkylene, Q1, Q2, (CH2)3C.tplbond.C, CH2C.tplbond.C(CH2)3; n = 1-3) were prepared as allergy inhibitors and cardiovascular agents. 6-(4-Acetyl-3-hydroxy-2-propylphenoxy)hexanoic acid was stirred with (PhO)2P(O)N3 and Et3N in DMF at 5° for 1.5 h followed by addition of 3-(aminobutyl)pyridine. Stirring was continued for 3 h at 5° and 16 h at 25° to give 75% I [R = Pr, R1 = 3-pyridyl, A = CONH, Y = (CH2)4, Z = (CH2)5] (II). In the guinea pig ileum model II antagonized SRS-A with an IC50 of 6 µM. Capsules were prepared containing II 100, lactose 99, cornstarch 20, talc 5, and Mg stearate 1 mg.

IT 87807-96-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation of, by aminobutylpyridine derivative)

RN 87807-96-3 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA INDEX NAME)




IT 79558-01-3P 79558-05-7P 87807-98-5P
87808-00-2P 110016-88-1P 110016-90-5P
110016-92-7P 110016-94-9P 110016-96-1P
110017-00-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and amidation of, by aminobutylpyridine derivative)

RN 79558-01-3 HCAPLUS


CN Benzoic acid, 3-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI)

(CA INDEX NAME)




RN 79558-05-7 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI)
(CA INDEX NAME)




RN 87807-98-5 HCAPLUS

CN Benzoic acid, 2-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA
INDEX NAME)




RN 87808-00-2 HCAPLUS

CN Benzoic acid, 3-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]- (9CI) (CA
INDEX NAME)




RN 110016-88-1 HCAPLUS

CN Benzoic acid, 3-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-2-ethoxy-
(9CI) (CA INDEX NAME)




RN 110016-90-5 HCAPLUS

CN Benzoic acid, 4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 110016-92-7 HCAPLUS

CN Benzoic acid, 4-[2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 110016-94-9 HCAPLUS

CN Benzoic acid, 3-[2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 110016-96-1 HCAPLUS

CN Benzoic acid, 2-[2-(4-acetyl-3-hydroxy-2-propylphenoxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 110017-00-0 HCAPLUS

CN Benzoic acid, 2-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI)
(CA INDEX NAME)



ACCESSION NUMBER: 1985:166756 HCAPLUS Full-text
 DOCUMENT NUMBER: 102:166756
 TITLE: Pharmaceutical ethanone compounds
 INVENTOR(S): Steggles, David James; Verge, John Pomfret
 PATENT ASSIGNEE(S): Lilly Industries Ltd., UK
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 132124	A1	19850123	EP 1984-304759	19840712 <--
EP 132124	B1	19870923		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FI 8402724	A	19850114	FI 1984-2724	19840706 <--
ZA 8405299	A	19850227	ZA 1984-5299	19840710 <--
IL 72363	A	19871231	IL 1984-72363	19840710 <--
HU 37920	A2	19860328	HU 1984-2707	19840711 <--
HU 192056	B	19870528		
CA 1222517	A1	19870602	CA 1984-458592	19840711 <--
US 4675334	A	19870623	US 1984-629647	19840711 <--
SU 1340585	A3	19870923	SU 1984-3770848	19840711 <--
PL 143372	B1	19880229	PL 1984-248668	19840711 <--
DK 8403436	A	19850114	DK 1984-3436	19840712 <--
AU 8430526	A	19850117	AU 1984-30526	19840712 <--
GB 2143817	A	19850220	GB 1984-17753	19840712 <--
GB 2143817	B	19870423		
JP 60038351	A	19850227	JP 1984-145208	19840712 <--
ES 534269	A1	19850916	ES 1984-534269	19840712 <--
AT 29878	T	19871015	AT 1984-304759	19840712 <--
PRIORITY APPLN. INFO.:			GB 1983-18889	A 19830713 <--
			EP 1984-304759	A 19840712 <--

OTHER SOURCE(S): CASREACT 102:166756; MARPAT 102:166756

ED Entered STN: 18 May 1985


AB Ph benzyl ethers I [R-R2 = H, OH, alkyl, alkylcarbonyl, halogen; R3, R4 = H, alkyl, (un)substituted Ph; R5 = 1H-tetrazol-5-yl, cyano; Z = alkylene, (un)substituted phenylalkylene; n = 0, 1], useful as leukotriene antagonists (no data) were prepared Thus, 1-(2,4-dihydroxy-3-propylphenyl)ethanone was treated with α, α' -dibromo-p-xylene to give phenylethanone II (R6 = Br), which was treated with KCN to give II (R6 = cyano). The latter compound was treated with NaN3 in presence of NH4Cl to give II (R6 = 1H-tetrazol-5-yl).

IT 95928-70-4P 95928-71-5P 95928-72-6P
95928-73-7P 95928-74-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN: 95928-70-4 HCAPLUS


CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 95928-71-5 HCAPLUS
 CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 95928-72-6 HCAPLUS
 CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[3-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 95928-73-7 HCAPLUS
 CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-[2-(1H-tetrazol-5-yl)ethyl]phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 95928-74-8 HCAPLUS
 CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[4-[3-(1H-tetrazol-5-yl)propyl]phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



38

L93 ANSWER 25 OF 115 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 26
 ACCESSION NUMBER: 1985:62239 HCAPLUS Full-text
 DOCUMENT NUMBER: 102:62239
 TITLE: Organic compounds and their pharmaceutical use
 INVENTOR(S): Goldsworthy, John; Marshall, Winston Stanley; Verge, John Pomfret
 PATENT ASSIGNEE(S): Lilly Industries Ltd., UK
 SOURCE: Brit. UK Pat. Appl., 8 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2128999	A	19840510	GB 1983-28106	19831020 <--
GB 2128999	B	19860702		
FI 8303770	A	19840422	FI 1983-3770	19831017 <--
ES 526528	A1	19850516	ES 1983-526528	19831017 <--
AU 8320257	A	19840503	AU 1983-20257	19831018 <--
ZA 8307749	A	19841128	ZA 1983-7749	19831018 <--
RO 87690	B3	19850930	RO 1983-112359	19831018 <--
SU 1277892	A3	19861215	SU 1983-3656355	19831018 <--
HU 34458	A2	19850328	HU 1983-3615	19831019 <--
HU 187928	B	19860328		
US 4595540	A	19860617	US 1983-543196	19831019 <--
PL 139497	B1	19870131	PL 1983-244215	19831019 <--
DK 8304829	A	19840422	DK 1983-4829	19831020 <--
JP 59093041	A	19840529	JP 1983-196925	19831020 <--
EP 110541	A1	19840613	EP 1983-306378	19831020 <--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DD 212254	A5	19840808	DD 1983-255824	19831020 <--
CA 1202632	A1	19860401	CA 1983-439422	19831020 <--
CS 255856	B2	19880315	CS 1983-7733	19831020 <--
US 4740514	A	19880426	US 1986-866663	19860527 <--
PRIORITY APPLN. INFO.:			GB 1982-30076	A 19821021 <--
			US 1983-543196	A3 19831019 <--

OTHER SOURCE(S): CASREACT 102:62239; MARPAT 102:62239

ED Entered STN: 24 Feb 1985


AB Substituted acylphenols I (R = H, alkyl; R1 = H, alkyl, alkenyl; R2 = XR3, cyano, thiocyno; R3 = 1H-tetrazol-5-yl; X = bond, S, SO, SO2; X1, X2 = O, S, SO, SO2; n = 2-6), leukotriene inhibitors (no data) were prepared. Thus 4-NCC6H4SH was alkylated with Br(CH2)3Cl to give 4-NCC6H4S(CH2)3Cl, which reacted with 2,4,3-(HO)2PrC6H2Ac to give 4,3,2-Ac(HO)PrC6H2O(CH2)3SC6H4CN- 4. Cyclization of the last with NaN3 gave (phenoxypropylthiophenyl)tetrazole II.

IT 93498-70-5P 93498-77-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and oxidation of)


RN 93498-70-5 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[3-[[4-(1H-tetrazol-5-yl)phenyl]thio]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 93498-77-2 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[2-[4-(1H-tetrazol-5-yl)phenoxy]ethyl]thio]phenyl]- (9CI) (CA INDEX NAME)




IT 93498-72-7P 93498-79-4P 93498-80-7P
93498-81-8P 93498-82-9P 93498-83-0P
93498-84-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 93498-72-7 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[2-[[4-(1H-tetrazol-5-yl)phenyl]thio]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 93498-79-4 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[3-[[4-(1H-tetrazol-5-yl)phenyl]thio]propyl]thio]phenyl]- (9CI) (CA INDEX NAME)



RN 93498-80-7 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[3-[[4-(1H-tetrazol-5-




IT 93498-75-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation oxidation of)

RN 93498-75-0 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[[3-[4-(1H-tetrazol-5-yl)phenoxy]propyl]thio]phenyl]- (9CI) (CA INDEX NAME)



L93 ANSWER 26 OF 115 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 27

ACCESSION NUMBER: 1982:51977 HCAPLUS Full-text

DOCUMENT NUMBER: 96:51977

TITLE: Phenoxyalkoxyphenyl derivatives

INVENTOR(S): Oxford, Alexander William; Ellis, Frank

PATENT ASSIGNEE(S): Glaxo Group Ltd., UK

SOURCE: Brit. UK Pat. Appl., 18 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2058785	A	19810415	GB 1980-28552	19800904 <--
GB 2058785	B	19830525		
DK 8003777	A	19810306	DK 1980-3777	19800904 <--
FI 8002783	A	19810306	FI 1980-2783	19800904 <--
AU 8062047	A	19810312	AU 1980-62047	19800904 <--
AU 543739	B2	19850502		
JP 56049336	A	19810502	JP 1980-122899	19800904 <--
ES 494769	A1	19810716	ES 1980-494769	19800904 <--
ZA 8005478	A	19810930	ZA 1980-5478	19800904 <--
ES 501436	A1	19820216	ES 1981-501436	19810415 <--
ES 501437	A1	19820401	ES 1981-501437	19810415 <--
PRIORITY APPLN. INFO.:			GB 1979-30849	A 19790905 <--

OTHER SOURCE(S): CASREACT 96:51977

ED Entered STN: 12 May 1984


AB The title compds. I [R = R₆, Z1R₆, OZ1R₆ (R₆ = CO₂H, 5-1H-tetrazolyl, N-5-1H-tetrazolecarboxamido; Z1 = C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene optionally substituted (o.s.) by ≥1 C1-3 alkyl); R1 = H, C1-6 alkyl; R2 = HCO, aroyl, o.s. C1-6 alkyl; R3 = C1-6 alkyl, C3-6 alkenyl; R4, R5 = H, halo, OH, C1-3 alkoxy, C1-6 alkyl, C3-6 alkenyl, C1-3 alkanoyl, NO₂, CO₂H; Z = saturated or unsatd. C1-10 carbon chain o.s. by OH and ≥1 C₆H₄ groups] were prepared I are potent antagonists of slow reacting substances of anaphylaxis and may be useful in treating hay fever, asthma, and skin afflictions (no data). E.g., NaH was stirred 15 min at 25° with 3-HOC₆H₄CO₂Me in DMF, and the mixture was treated by addition of NaI and 1-[4-(3-chloropropoxy)-2-hydroxy-3-propylphenyl]ethanone and heated 3 h at 110° to give I [R = CO₂Me-3, R1 = R4 = R5 = H, R2 = COMe, R3 = Pr, Z = (CH₂)₃] which was saponified to the corresponding acid by refluxing 20 min in 0.33N aqueous NaOH. Compns. containing I are described.

IT 79557-91-8P 79557-93-0P 79558-01-3P
79558-04-6P 79558-05-7P 79558-06-8P
79558-13-7P 79558-14-8P 79558-28-4P
79558-34-2P 79558-37-5P 79558-39-7P
79558-42-2P 79558-43-3P 79558-45-5P
79558-46-6P 79558-47-7P 79558-51-3P
79558-53-5P 79558-57-9P 79558-60-4P
79558-61-5P 79558-62-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anaphylactic antagonist)


RN 79557-91-8 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-5-bromo-2-hydroxy- (9CI) (CA INDEX NAME)




RN 79557-93-0 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2-hydroxy-5-nitro- (9CI) (CA INDEX NAME)




RN 79558-01-3 HCAPLUS

CN Benzoic acid, 3-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 79558-04-6 HCAPLUS

CN Benzenecarboxylic acid, 3-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 79558-05-7 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 79558-06-8 HCAPLUS

CN Benzenepropanoic acid, 3-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 79558-13-7 HCAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- (9CI) (CA INDEX NAME)




RN 79558-14-8 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2-hydroxy-3-propyl- (9CI) (CA INDEX NAME)




RN 79558-28-4 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 79558-34-2 HCAPLUS

CN Benzoic acid, 3-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-5-hydroxy- (9CI) (CA INDEX NAME)



RN 79558-37-5 HCAPLUS

CN Ethanone, 1-[2-hydroxy-3-propyl-4-[3-[3-(1H-tetrazol-5-yl)phenoxy]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 79558-39-7 HCAPLUS

CN Benzoic acid, 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2-hydroxy-3-(2-propenyl)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1966:447469 HCAPLUS Full-text
 DOCUMENT NUMBER: 65:47469
 ORIGINAL REFERENCE NO.: 65:8822h,8823a-h,8824a-h,8825a,8826a
 TITLE: β -Aminoacylphenoxy- and β aminoacylphenylthio-
 derivatives of monocarboxylic acids
 INVENTOR(S): Schultz, Everett M.; Sprague, James M.
 SOURCE: 23 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3251064		19660510	US 1962-237288	19611206 <--
PRIORITY APPLN. INFO.:			US	19611206 <--

ED Entered STN: 22 Apr 2001


AB Title compds. (I), which possess diuretic, natriuretic, and chloruretic properties, were prepared by condensation of acylphenoxyacetic acids (II) or acylphenylthioacetic acids (III) with secondary amines and HCHO. Acyl phenols (IV) were prepared by acylation of anisoles, by Fries rearrangements of Ph esters, or by hydrolysis of appropriate diazonium compds. Condensation of IV with Et α -halo-carboxylates in the presence of a base gave II. Thus, to a mixture of 38.8 g. 2,3-dichloroanisole and 25 g. cyclopentaneacetyl chloride in 250 ml. CS₂ was added 46.6 g. AlCl₃. After 5 hrs. at 50-60° the CS₂ was distilled, and 200 ml. heptane and 26.67 g. AlCl₃ added. After 2 hrs. on a steam bath the mixture was worked up to obtain 28 g. 2',3'-dichloro-4'-hydroxy-1-cyclopentaneacetophenone (V), m. 86-8°. A solution of 0.1 mole V in 60 ml. glyme was added to 0.1 mole NaH in 40 ml. glyme. BrCH₂CO₂Et (0.11 mole) was added during 25 min. and the mixture refluxed 1 hr. to give a 76% yield of 4-(cyclopentylacetyl)-2,3- di-chlorophenoxyacetic acid, m. 127-8°. Compds. in the 1st table were prepared similarly. Condensation of phenoxyalkanoic or phenylthioalkanoic acids with acyl halides in the presence of AlCl₃ in CS₂ solvent also gave II and III. Thus, to a mixture of 216 g. AlCl₃ in 400 ml. CS₂ was added 93.29 g. 3-ClC₆H₄CH₂CO₂H followed by 57.8 g. EtCOCl during 0.5 hrs. at 22-6°. After 1 hr. at room temperature and 3 hrs. at 50°, the mixture was worked up to obtain 77.5 g. 3-chloro-4-propionylphenoxyacetic acid, m. 107.5-109°. Similarly were prepared the II in the 2nd table. A mixture of 5.12 g. 3-chloro-4- butyrylphenoxyacetic acid, 0.7 g. paraformaldehyde, 1.78 g. Me₂NH.HCl and 4 drops HOAc was warmed on a steam bath 1.5 hrs. with occasional application of slight vacuum for 1-min. intervals. The crude mixture was triturated with Me₂CO to recover 3-chloro-4-[g- (dimethylaminomethyl)butyryl]phenoxyacetic acid hydrochloride, m. 127-9°. Other I were prepared similarly from II where Y₂N.HCl = Me₂N.HCl and A = 0 as shown in the 3rd table. Condensation of II or III with other amine hydrochlorides gave the Ia in the 4th table.

IT 1160-52-7P, Benzoic acid, p-(4-butyryl-3-chlorophenoxy)-
1163-60-6P, m-Toluic acid, α -(4-butyryl-3-chlorophenoxy)-
1164-19-8P, p-Toluic acid, α -(4-butyryl-3-chlorophenoxy)-
1234-31-7P, p-Toluic acid, α -(3-chloro-4-propionylphenoxy)-
 RL: PREP (Preparation)

(preparation of)


RN 1160-52-7 HCAPLUS

CN Benzoic acid, p-(4-butyryl-3-chlorophenoxy)- (7CI, 8CI) (CA INDEX NAME)




RN 1163-60-6 HCAPLUS

CN m-Toluic acid, α -(4-butyl-3-chlorophenoxy)- (7CI, 8CI) (CA INDEX NAME)



RN 1164-19-8 HCAPLUS

CN p-Toluic acid, α -(4-butyl-3-chlorophenoxy)- (7CI, 8CI) (CA INDEX NAME)



RN 1234-31-7 HCAPLUS

CN p-Toluic acid, α -(3-chloro-4-propionylphenoxy)- (7CI, 8CI) (CA INDEX NAME)

